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Background: Cancer-associated fibroblasts (CAF) are primed for apoptosis by an unknown mechanism.
Results: PDGF, which activates CAF, increases cellular Puma levels, sensitizing CAF to Bak activation and enhanced apoptosis
by BH3 mimetics in vitro and in vivo.
Conclusion: These observations elucidate the mechanisms underlying apoptotic priming of CAF.
Significance: BH3 mimetic-induced Bak activation with CAF apoptosis is a therapeutic strategy for treating desmoplastic
cancers.
Desmoplastic malignancies such as cholangiocarcinoma
(CCA) are characterized by a dense stroma containing an abun-
dance of myofibroblasts termed cancer-associated fibroblasts
(CAF). The CAF phenotype represents an “activated state” in
which cells are primed for cell death triggered by BH3mimetics.
Accordingly, this primed statemay be therapeutically exploited.
To elucidate themechanismsunderlying this poorly understood
apoptotic priming, we examined the role of platelet-derived
growth factor (PDGF) in CAF priming for cell death given its
prominent role in CAF activation. PDGF isomers PDGF-B and
PDGF-D are abundantly expressed in CCA cells derived from
human specimens. Either isomer sensitizes myofibroblasts to
cell death triggered by BH3mimetics. Similar apoptotic sensiti-
zation was observed with co-culture of myofibroblasts and CCA
cells. Profiling of Bcl-2 proteins expressed by PDGF-primed
myofibroblasts demonstrated an increase in cellular levels of
Puma. PDGF-mediated increases in cellular Puma levels
inducedproapoptotic changes inBak,which resulted in its bind-
ing to Bcl-2. Short hairpin RNA-mediated down-regulation of
Puma conferred resistance to PDGF-mediated apoptotic
priming. Conversely, the BH3 mimetic navitoclax disrupted
Bcl-2/Bak heterodimers, allowing Bak to execute the cell
death program. Treatment with a Bcl-2-specific BH3
mimetic, ABT-199, reduced tumor formation and tumor bur-
den in a murine model of cholangiocarcinoma. Collectively,
these findings indicate that apoptotic priming of CAF by
PDGF occurs via Puma-mediated Bak activation, which can
be converted to active full-blown apoptosis by navitoclax or
ABT-199 for therapeutic benefit.
Much of the effort in cancer biology and therapy has focused
on directly targeting and eradicating neoplastically trans-
formed cells. However, achieving effective cancer cell-directed
therapy has been challenging because of the diverse alterations
in these transformed cells and the continued accumulation of
abnormalities due to genomic instability (1, 2). In contrast, the
tumor stroma appears to be more genetically uniform and rep-
resents an additional therapeutic target (1, 3–5). Exploiting the
dependence of cancer cells on the tumor microenvironment
will require a further in-depth understanding of the dynamic
reciprocal interaction between cancer cells and the surround-
ing stroma.
The hallmark of desmoplastic tumors is a dense stroma
characterized by an abundance of -smooth muscle actin
(-SMA)4-positive myofibroblasts termed cancer-associated
fibroblasts (CAF), which play a pivotal role in cancer progres-
sion (6–8). This dense stroma, which is found in a number of
solid tumors, including cholangiocarcinoma, pancreatic can-
cer, and certain subtypes of breast cancer, has been proposed as
a potential target for anticancer therapy (3, 6, 9, 10).
Increased apoptotic sensitivity has been well described in
several “activated” cell states, including CAF (3, 11, 12). For
instance, activated T-cells at the end of an immune response
and activated hepatic stellate cells (HSC) in fibrotic liver injury
have an increased susceptibility to cell death (11, 13). Indeed,
myofibroblast apoptosis as well as their reversal to a quies-
cent phenotype is associated with regression of liver fibrosis
(11, 12). This increased apoptotic sensitivity has been linked
to enhanced ability to activate the mitochondrial pathway of
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apoptosis, a phenomenon termed “mitochondrial priming”
(14, 15).
The mitochondrial apoptotic pathway is regulated by the
Bcl-2 family of proteins. Activation of Bak or Bax, two of the
proapoptotic members of this family, results in their oligomer-
ization, insertion in the outer mitochondrial membrane, and
permeabilization of that membrane to allow release of cyto-
chrome c and other apoptogenic proteins from the mitochon-
drial intermembrane space into the cytosol (16). Antiapoptotic
members of this family, including Bcl-2, Bcl-xL, and Mcl-1, act
in part by binding Bak or Bax and preventing their oligomeri-
zation. BH3-only proteins such as Puma, Bim, Bid, Bad, and
Noxa, which share only the 15-amino acid BH3 homology
domain with the other Bcl-2 proteins, act as initiators of cell
death by directly activating Bak and Bax or by neutralizing anti-
apoptotic proteins (17).
When cells are “primed” for apoptosis, BH3mimetics (small,
organic compounds that function like BH3-only proteins to
bind antiapoptotic Bcl-2 family members and displace BH3-
only proteins from them) are readily able to induce apoptosis.
For example, we recently reported that CAF from cholangio-
carcinoma (CCA), a prototypic desmoplastic cancer for the
study of CAF biology (6), are primed for apoptosis (3). In par-
ticular, the BH3mimetic navitoclax is able to not only kill these
myofibroblasts ex vivo but also inhibit tumor growth and
metastasis in a syngeneic orthotopic transplantation animal
model of CCAby depletingCAF from the tumormicroenviron-
ment (3). The mechanistic basis for the sensitivity of CAF to
BH3 mimetics, however, is unknown.
Platelet-derived growth factor (PDGF) is one of the most
abundant growth factors in the CCA tumormicroenvironment
secreted by tumor cells (19). PDGF family members, particu-
larly PDGF-B and PDGF-D, have been implicated in promoting
proliferation, survival, and CAF migration in these desmoplas-
tic tumors (19–21). These important effects of PDGF in CAF
prompted us to examine whether PDGF also participates in
priming. Herein, we report that PDGF induces priming ofmyo-
fibroblasts but not CCA cells. We further demonstrate that
PDGF increases cellular Puma levels in myofibroblasts, leading
to Puma-dependent binding of Bak to Bcl-2. BH3mimetics that
disrupt this Puma-initiated Bak/Bcl-2 interaction cause Bak-
mediated cell death of the CAF. These observations provide a
mechanistic basis for mitochondrial “priming” of CAF in CCA
and other desmoplastic tumors.
EXPERIMENTAL PROCEDURES
Cell Culture—ThehumanCCAcell linesKMCH (22), KMBC
(23), HuCCT-1 (24), and Mz-ChA-1 (25), the human hepatic
myofibroblast LX-2 (26), quiescent human fibroblasts (hFB)
obtained fromATCC, and HSCs kindly provided by V. H. Shah
(Mayo Clinic, Rochester, MN), were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine
serum, penicillin (100 units/ml) and streptomycin (100 g/ml)
under standard conditions. The non-malignant SV40-immor-
talized human cholangiocyte cell line H69 was maintained as
previously described (27, 28).
Materials—Navitoclax andABT-199 (Active Biochem,Hong
Kong)were dissolved in dimethyl sulfoxide and added to cells in
a final concentration of 1 M from 1000-fold concentrated
stocks. Recombinant human PDGF-B, recombinant human
PDGF-D, and recombinant human hepatocyte growth factor
(R&D Systems, Minneapolis, MN) as well as recombinant
human connective tissue growth factor (PeproTech, RockyHill,
NJ) were reconstituted according to the manufacturers’ proto-
cols and added to cells at a final concentration of 50 ng/ml.
Anti-human PDGFRB (R&D Systems) was added to cells at a
final concentration of 20 g/ml.
Immunofluorescence in Human Cholangiocarcinoma
Samples—Frozen tissue samples of human CCA and corre-
sponding samples of normal liver tissue (n 12) were obtained
with Institutional ReviewBoard approval. 5-mfrozen sections
were prepared on a cryomicrotome (Leica, Buffalo Grove, IL),
air-dried, and stored at 80 °C. Tissue sections were fixed for
10 min in 100% acetone at 20 °C, blocked for 1 h at room
temperature with calcium- and magnesium-free Dulbecco’s
phosphate-buffered saline (PBS) containing 5% bovine serum
albumin (BSA) and 0.1% glycine, and subsequently incubated
with primary antibody for 12 h at 4 °C. Antibodies were diluted
in PBS containing 5%BSA and 0.1% glycine. Primary antibodies
usedwere-SMA (1:300; Abcam, ab7817), CK7 (1:300; Abcam,
ab9021), PDGF-B (1:300; Abcam, ab21234), and PDGF-D
(1:300; Abnova, H00080310-D01). After washing, slides were
incubated with Alexa Fluor 488 anti-rabbit IgG (PDGF-B and
PDGF-D; 1:1000; Invitrogen, A21441) or Texas Red-X anti-
mouse IgG (CK7, -SMA; 1:1000; Invitrogen, T6390) for 1 h in
the dark at room temperature, washed again, and mounted
using Prolong Antifade with 4,6-diamidino-2-phenylindole
(DAPI; Invitrogen) to visualize the nuclei. The slides were ana-
lyzed on an LSM780 confocal microscope (Zeiss, Jena, Ger-
many) equipped with an ultraviolet laser.
mRNA Analysis—For gene expression studies, mRNA was
isolated from fresh-frozen tissue sections and cells using the
RNeasy PlusMiniKit (Qiagen,Hilden,Germany). Reverse tran-
scription was performed using the Moloney murine leukemia
virus reverse transcriptase and random primers (Invitrogen).
Real time polymerase chain reaction (PCR; Light Cycler, Roche
Applied Science) for quantification of the cDNA template was
performed using SYBR Green (Roche Applied Science) as the
fluorophore (29). The primers used in PCR reactions were:
PDGF-B forward (5-CTGGCATGCAAGTGTGAGAC-3)
and PDGF-B reverse (5-CGAATGGTCACCCGAGTT-3);
PDGF-D forward (5-CCATGACCGGAAGTCAAAAG-3)
and PDGF-D reverse (5-ATTCCTGGGAGTGCAACTGT-
3); Puma forward (5-GACCTCAACGCACAGTACGA-3)
and Puma reverse (5-GAGATTGTACAGGACCCTCCA-3).
Expression was normalized to 18 S rRNA (Ambion, Austin,
TX). Relative gene expression was calculated according to the
 CT method.
Quantification of Apoptosis—Cells were grown to subconflu-
ency in 96-well plates, and respective treatments were subse-
quently added. Cellular nuclear morphology was assessed by
fluorescent microscopy after staining with DAPI (Sigma), and
apoptosis was quantified as previously described (30). Caspase-
3/7 activity was quantified utilizing a commercially available
assay (Apo-ONE homogeneous caspase-3/7 assay, Promega
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Corp., Madison, WI) and a multi-detection microplate reader
(Biotek, Winooski, VT).
Generation of Stable Transfectants—HEK 293T cells were
transfected with pCMV-VSV-G (Addgene), pCMV-dR8.2 dvpr
(Addgene), and the lentiviral shPuma (Sigma, NM_014417.2-
719; Sigma, NM_014417.2-785) and shPDGFRB constructs
(Sigma, NM_002609.3-3724; Sigma, NM_002609.x-2371), re-
spectively, using Lipofectamine LTX reagent (Invitrogen) to
package the shPuma and shPDGFRB containing lentiviruses.
Medium was passed through a 0.45-m pore filter, and Poly-
brene (Sigma) was then added to a final concentration of 8
g/ml. Target HSC cells grown to 50% confluency were incu-
bated with lentivirus-containing medium from the HEK 293T
cells for 3 h before medium was replaced with fresh noninfec-
tiousmedium. Infectionwas again repeated 24 h after the initial
exposure. Infected HSC were split into selection medium con-
taining 2.5 g/ml puromycin. Cell lysates were prepared from
shPuma and shPDGFRB cells to confirm knockdown of
shPuma and shPDGFRB protein by Western blotting. Stably
transfected shBax and shBak clones were generated as previ-
ously described in detail (3).
Co-culture and Conditioned Medium Experiments—Cell co-
culture experiments were performed using a Transwell insert
co-culture system (24 wells) equipped with 0.4-m pore size
polyester inserts (Corning Costar, Acton,MA) according to the
manufacturer’s recommendations. Briefly, HSC, hFB, and
shPDGFRB-HSC cells were plated alone or with human CCA
cell lines in the transwell insert co-culture system (HSC, hFB, or
shPDGFRB-HSC in the bottom wells and KMCH, KMBC,
HuCCT-1, Mz-ChA-1, or H69 in the inserts). Initially, all cells
FIGURE 1. PDGF-B and PDGF-D are increased in CCA cells in human resected specimens. A, expression of PDGF-B and PDGF-D was quantified in human
resected CCA specimens and the corresponding normal livers by quantitative real-time-PCR. Mean S.E. are depicted for n 12; **, p 0.01. B, immunofluo-
rescence was used to detect PDGF-B and PDGF-D expression in CCA cells (CK7-positive) compared with CAF (-SMA-positive) (left panel). The number of
PDGF-B or PDGF-D positive CCA cells and CAF was quantified in five high power fields and expressed as a percentage of total (right panel). Means S.E. are
depicted for n 5. ***, p 0.001. Original magnification, 63.
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were plated alone overnight. The co-culture insert chambers
containing the CCA cell lines were then transferred the next
day. After 24 h, cells were treated with vehicle or navitoclax, 1
M. After 48 h, cells in the bottom wells were analyzed for
apoptosis using DAPI staining as described above. Caspase-3/7
assay was performed utilizing conditioned medium harvested
from CCA cell lines. Briefly, HSC, hFB, and shPDGFRB-HSC
were plated in 96-well plates. After 24 h, conditioned medium
from CCA cell lines (KMCH, KMBC, HuCCT-1, Mz-ChA-1)
was harvested, passed through a 0.45-mpore filter, and added
to respective wells in the plates containing HSC, hFB, or
shPDGFRB-HSC. After 24 h, cells were treated with vehicle or
navitoclax 1 M. After 48 h of navitoclax treatment, apoptosis
was assessed by quantification of caspase-3/7 activity as
described above.
Immunoblot Analysis—Using whole-cell lysates prepared as
previously detailed (31), proteins were resolved by SDS-PAGE
and transferred to nitrocellulose or polyvinylidene difluoride
membranes depending on the protein of interest. Membranes
were blotted with primary antibody at the indicated dilutions.
Antibody sources are as follows: Bak (G-23; 1:500), Bax (N-20;
1:500), Mcl-1 (S-19; 1:500), and actin (C-11; 1:500) from Santa
Cruz Biotechnology (Santa Cruz, CA); Bid (AF860; 1:500) from
R&D Systems; Bim (2819S; 1:500) and Bcl-xL (54H6; 1:500)
from Cell Signaling (Danvers, MA); Bcl-2 (clone 124; 1:300)
from DAKO (Carpinteria, CA); Puma (PRS3041; 1:500) from
Sigma. Horseradish peroxidase-conjugated secondary antibod-
ies for mouse, rabbit, and goat (1:3000) were obtained from
Santa Cruz (Santa Cruz, CA), and fluorochrome-labeled sec-
ondary antibodies for mouse, rabbit, and goat (1:10000) were
from LICOR (Lincoln, NE). Proteins were visualized with
enhanced chemiluminescence reagents (ECL/ECL Plus, Amer-
sham Biosciences) and Kodak X-Omat film or by Odyssey
(LICOR) infrared scanning.
Analytical Gel Filtration—Cells were grown to confluence,
and respective treatments were added. Cells were lysed using
CHAPS buffer (1% CHAPS, 1% glycerol, 150 mM NaCl, 5 mM
DTT, and 20mMHEPES, pH 7.5). 200-l aliquots of cell lysates
were subjected to fast protein liquid chromatography (FPLC) at
4 °C on Superdex S200 (GEHealthcare) as previously described
(32). 500-l fractions were analyzed by SDS-PAGE followed by
immunoblot analysis.
Immunoprecipitation of Bcl-2—HSC were grown on 15-cm
tissue culture dishes to subconfluency, and respective treat-
ments were added. Cells were subsequently lysed in cold
CHAPS lysis buffer (1% CHAPS, 150 mM NaCl, 20 mM HEPES,
1% glycerol, 3% thiodiglycol, 1 mM EGTA, 1 mM sodium
orthovanadate, 10mM sodiumpyrophosphate, 1mMPMSF, 1
protease inhibitor mix, 100 mM sodium fluoride, 25 nM micro-
cystin). Lysates were centrifuged for 15 min at 15,000  g to
pellet cellular debris. Protein concentrationwas determined via
Bradford assay. 400 g of total protein was precleared by incu-
bationwith 40l of proteinGSepharose beads (GEHealthcare)
for 1 h at 4 °C. Beads cross-linked to anti-Bcl-2 (clone 124;
DAKO) or control mouse IgG (Santa Cruz) were prepared as
previously described (33). 40 l of control IgG or Bcl-2 cross-
linked beads were added to the precleared 400g of total lysate
protein and incubated rotating overnight at 4 °C. After sedi-
mentation at 8000  g for 2 min, beads were rapidly washed 4
times with CHAPS lysis buffer, resuspended in sample buffer (4
M urea, 2% (w/v) SDS, 62.5 mM Tris-HCl, pH 6.8, 1 mM EDTA,
and 5% (v/v) 2-mercaptoethanol), and heated for 20 min at
65 °C to release bound polypeptides. Immunoprecipitated
Bcl-2 and 1/5 dilution of input were subjected to SDS-PAGE,
transferred to nitrocellulose membrane, and probed with anti-
bodies to Bak and Bcl-2 as indicated in the figure legends.
RNA Interference—A small interfering RNA (siRNA) (Ori-
gene, Rockville,MD)was employed to silenceBcl-2. Cells trans-
fected with scramble siRNA were used as control. Cells were
grown in 24-well plates and transiently transfected with 30 nM
siRNAusing siTran 1.0 (Origene) in a total transfection volume
of 600 l of Opti-MEM I (Invitrogen). Respective treatments
were added after 24 h.
Murine Model of Cholangiocarcinoma—All animal experi-
ments were performed in accordance with a protocol approved
by theMayoClinic Institutional AnimalCare andUseCommit-
tee. A murine model of CCA, driven by sleeping beauty trans-
posase-mediated biliary introduction of constitutively active
AKT (myr-AKT) and Yes-associated protein (YAPS127A) (34)
followed by interleukin-33 (IL-33) administration, was used
(35). Each animal was given intraperitoneal injections of 1g of
IL-33 (R&D Systems) starting on post-operative day 1 for 3
days. Fromweek 4 to week 6, mice received either ABT-199 (50
mg/kg/day) or vehicle via daily oral gavage. Animals were
euthanized at the end of 10 weeks and examined for the pres-
ence of tumor and metastases.
Immunohistochemistry and Terminal Deoxynucleotidyl-
transferase dUTP Nick-end Labeling (TUNEL) Assay in Mice
Liver Specimens—Liver tissue from euthanized mice was fixed
in 4% paraformaldehyde for 48 h, embedded in paraffin, and
sectioned into 3.5-m slices. Paraformaldehyde-fixed paraffin-
embedded liver tissue sections were deparaffinized, hydrated,
and incubated with antibody against -SMA (Abcam; 1:500)
overnight at 4 °C. Bound antibodies were detected with biotin-
conjugated secondary antibodies and diaminobenzidine (Vec-
tor Laboratories, Burlingame, CA) as a substrate, and the tissue
slices were counterstained with hematoxylin. The fluorescent
TUNEL assay on liver tissue (In situ cell death detection kit;
FIGURE2.PDGF-BandPDGF-DsensitizehFBandHSC,butnotCCAcells, tonavitoclax-inducedapoptosis.A, HSCand fourdifferent typesofquiescenthFB
(hFB 1–4) were treated with vehicle, navitoclax for 48 h, and PDGF-B for 24 h or PDGF-B for 24 h followed by the addition of navitoclax for 48 h. Similarly, HSC
cells and two hFB cell types were treated with vehicle (Veh), navitoclax (Nav), PDGF-D, or PDGF-D for 24 h followed by the addition of navitoclax for 48 h.
Apoptosis was quantified morphologically using DAPI staining plus fluorescence microscopy (upper panels) and biochemically by measuring caspase-3/7
activity (lower panels). Mean S.E. are depicted for n 3. **. p 0.01; ***, p 0.001. B, hFB andHSCwere treatedwith vehicle, hepatocyte growth factor (HGF),
connective tissue growth factor (CTGF), and navitoclax for 24 h followed by the addition of navitoclax for 48 h or connective tissue growth factor for 24 h
followed by the addition of navitoclax for 48 h. Apoptosis was quantified using DAPI plus fluorescencemicroscopy (upper panels) and bymeasuring caspase-
3/7 activity (lower panels). Mean  S.E. are depicted for n  3. C, four different human CCA cell lines (KMCH, KMBC, HuCCT-1, Mz-ChA-1) were treated as
described inA. ApoptosiswasquantifiedusingDAPI plus fluorescencemicroscopy (upper panels) andbymeasuring caspase-3/7 activity (lower panels).Mean
S.E. are depicted for n 3.
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Roche Applied Science) was performed on paraffin-embedded
liver tissue sections. Briefly, paraformaldehyde-fixed paraffin-
embedded liver tissue sections were deparaffinized and
hydrated. The TUNEL assay was then performed using the
manufacturer’s protocol, and tissue slices were mounted with
ProLong Gold antifade reagent with DAPI (Invitrogen). Apo-
ptotic cells were quantified by counting TUNEL-positive nuclei
in 10 randommicroscopic fields (63) using the LSM780 con-
focal microscope (Zeiss, Jena, Germany).
Biochemical Analysis—Serum alanine aminotransferase
activity was determined using a standardized and automated
procedure of the diagnostic laboratory of the Mayo Clinic.
Statistical Analysis—Data represent at least three indepen-
dent experiments and are expressed as the mean S.E. Differ-
ences in experiments with two groupswere compared using the
two-tailed Student’s t test or the Fisher’s exact test. Differences
were considered as significant at levels of p 0.05.
RESULTS
PDGF Is Abundantly Expressed in Human CCA Specimens—
PDGF family members, particularly PDGF-B and PDGF-D,
have been implicated in promoting proliferation, survival, and
CAF migration in desmoplastic tumors (19–21). Initially, we
sought to identify which PDGF isomer is prominently ex-
pressed in CCA. Quantitative RT-PCR demonstrated that both
PDGF-B and PDGF-D mRNA are abundantly expressed in all
human CCA samples as compared with corresponding non-
tumor liver tissue (Fig. 1A). In further experiments, we exam-
ined the cellular distribution of these isomers within the CCA
tissue by immunofluorescence (Fig. 1B). Co-staining with
-SMA and CK7, which were used to identify activated CAF
and CCA cells, respectively, demonstrated that PDGF-B and
PDGF-D are localized predominantly in the CCA cells and to a
lesser extent in CAF. These observations indicate that both iso-
forms are potentially important in CCA biology.
PDGF Selectively Sensitizes Myofibroblasts to Navitoclax-
triggered Apoptosis—CAF are likely derived from several differ-
ent cell types, including portal fibroblasts, HSC, and perhaps
even bone marrow-derived precursor cells (36–38). Therefore,
we stimulated both hFB and HSC to obtain the activated myo-
fibroblast state. Cells were pretreated with the growth factors
PDGF-B, PDGF-D, hepatocyte growth factor, and connective
tissue growth factor (all known to be expressed in CCA (6, 19,
21)) to achieve an activated phenotype and subsequently
exposed to the BH3 mimetic navitoclax. Pretreatment with
PDGF-B and PDGF-D, but not hepatocyte growth factor or
connective tissue growth factor, significantly increased the sen-
sitivity of hFB and HSC to navitoclax-mediated apoptosis as
assessed morphologically (Fig. 2, A and B, upper panels) and
biochemically (Fig. 2, A and B, lower panels). In comparison,
navitoclax alone did not induce apoptosis in quiescent hFB.
HSC, which represent a semiactivated state, displayed modest
navitoclax sensitivity without growth factors but were further
sensitized by PDGF-B or PDGF-D pretreatment. In contrast to
the myofibroblast cells, human CCA cells did not exhibit apo-
ptotic sensitization to navitoclax after PDGF treatment (Fig.
2C), likely due to their known overexpression of Mcl-1, which
does not bind navitoclax (3). Given that either PDGF-B or
PDGF-D primed myofibroblasts for cell killing by navitoclax,
we elected to use PDGF-B for the preponderance of our
remaining studies.
Co-culture of Myofibroblast Cells with CCA Cells Induces
Apoptotic Priming—Having observed that PDGF induces apo-
ptotic priming, we sought to determine whether this sensitiza-
tion could be replicated by co-culture of hFB and HSC with
CCA cell lines.We first assessed expression of PDGF ligands in
four different human CCA cell lines. Both PDGF-B and
PDGF-D were abundantly expressed in all four CCA cell lines
(Fig. 3A). Next, quiescent hFB and HSC were co-cultured with
these four CCA cell lines and subsequently treated with navito-
clax. Apoptotic sensitization, similar to that observed with
PDGF,was observed inmyofibroblast cells co-culturedwith the
CCA cell lines but not with H69 cells, which do not express
PDGF-B or -D (Fig. 3B). Similarly, conditioned medium from
CCA cell lines sensitized myofibroblasts to navitoclax-induced
cell death (Fig. 3C).
Both PDGF-B and PDGF-D have high affinity for the recep-
tor PDGFRB (39). The observed sensitization to apoptosis by
co-culturewithCCAcells or treatmentwith conditionedmedia
from CCA cells was abrogated both in myofibroblasts with
short hairpin RNA (shRNA)-targeted knockdown of PDGFRB
or with the addition of antibody neutralizing PDGFRB (Fig. 3,
D–F). Taken together, these data strongly suggest that PDGF
can mediate apoptotic priming in myofibroblasts.
PDGF Increases Cellular Levels of Puma in Myofibroblasts—
To determine whether modulation of Bcl-2 proteins is respon-
sible for the observed myofibroblast priming for cell death, we
profiled the pro-apoptotic Bcl-2 proteins Bax and Bak, the anti-
apoptotic Bcl-2 proteinsMcl-1, Bcl-2, and Bcl-xL, and the BH3-
FIGURE 3. Co-culturing hFB or HSC with CCA cell lines significantly increases navitoclax-induced apoptosis. A, expression of PDGF-B and PDGF-D was
quantified in thehumanCCAcell linesKMCH,KMBC,HuCCT-1, andMz-ChA-1and thehumancholangiocyte cell lineH69byquantitative real-time-PCR.Mean
S.E. are depicted for n 3. *, p 0.05; **, p 0.01; ***, p 0.001 versusH69. B, two hFB cell lines and HSCwere co-culturedwith each of the four CCA cell lines.
HSCwere also co-culturedwithH69 cells. After 24h, navitoclax (Nav) or vehicle (Veh) was added for an additional 48h. Apoptosiswas assessedbyDAPI staining
and fluorescencemicroscopy. Means S.E. are depicted for n 3. *, p 0.05; **, p 0.01; ***, p 0.001. C, conditionedmedia from the human CCA cell lines
KMCH, KMBC, HuCCT-1, and Mz-ChA-1 was added to quiescent hFB and HSC for 24 h. Navitoclax or vehicle was subsequently added for 48 h. Apoptosis was
assessed by fluorometric measurement of caspase-3/7 activity. Means S.E. are depicted for n 3. *, p 0.05; **, p 0.01; ***, p 0.001. D, HSC cells with
shRNA-targeted knockdown of the PDGF receptor, PDGFRB (Western blotting for PDGFRB in empty vector (EV) and shPDGFRB HSC cells; left panel) were
co-culturedwith fourhumanCCAcell lines (KMCH, KMBC,HuCCT-1,Mz-ChA-1). After 24h, navitoclaxor vehiclewas added for anadditional 48h.Apoptosiswas
assessed by DAPI staining and fluorescencemicroscopy (right panel). Means S.E. are depicted for n 3. E, HSC cells with shRNA-targeted knockdown of the
PDGF receptor, PDGFRB, were treated with conditioned media from four human CCA cell lines (KMCH, KMBC, HuCCT-1, Mz-ChA-1). After 24 h, navitoclax or
vehicle was added for an additional 48 h. Apoptosis was assessed by fluorometric measurement of caspase-3/7 activity. Means S.E. are depicted for n 3.
* p 0.05. F, HSC cells were co-cultured with four human CCA cell lines (KMCH, KMBC, HuCCT-1, Mz-ChA-1). Antibody neutralizing PDGFRB was added to the
respective groups. After 24 h, navitoclax or vehicle was added for an additional 48 h. Apoptosis was assessed by DAPI staining and fluorescence microscopy
(right panel). Mean S.E. are depicted for n 3. *, p 0.05; ***, p 0.001.
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only proteins Bim, Bid, and Puma by immunoblot analysis.
Increased expression of the pro-apoptotic BH3-only protein
Puma was consistently observed in PDGF-B-treated cells com-
pared with vehicle-treated cells (Fig. 4A). Puma mRNA levels
were similar in PDGF-B and vehicle-treated cells (Fig. 4B), sug-
gesting that Pumaup-regulationmight reflect posttranslational
differences. A PDGF-B-mediated decrease in Bcl-2 was also
observed, albeit not consistently in all the myofibroblast cell
lines.
Bak Activation Leads to Navitoclax-triggered Apoptosis in
CAF—The mitochondrial pathway of cell death is triggered
when either Bak or Bax oligomerizes in themitochondrial outer
membrane, causing mitochondrial outer membrane permeabi-
lization with egress of apoptogenic mediators from the mito-
chondrial intermembrane space into the cytosol (16). Bak or
Bax protein complexes in PDGF-B-treated cells were examined
by fast protein liquid chromatography. Interestingly, we found
that both PDGF-B alone and the combination of PDGF-B and
navitoclax led to shifting of Bak frommonomers to higher order
protein complexes (Fig. 5A). As PDGF-B sensitizes to but does
not trigger apoptosis, we hypothesized that PDGF-B induces
binding of Bak to an antiapoptotic Bcl-2 family protein (Mcl-1,
Bcl-2, Bcl-xL), accounting for the shift to a higher molecular
weight. Indeed, a shift in Bcl-2 from monomers to larger-sized
protein complexes occurred with PDGF-B treatment (Fig. 5B).
In contrast,Mcl-1 and Bcl-xL did not have a shift to larger-sized
protein complexes with PDGF-B treatment (data not shown).
Consistent with these results, PDGF-B treatment also resulted
in increased association of Bak and Bcl-2, as indicated by co-
immunoprecipitation of the endogenous proteins (Fig. 5C), and
the addition of navitoclax disrupted this complex. These obser-
vations are consistent with amodel inwhich PDGF-B facilitates
binding of Bak to Bcl-2, leading to priming for cell death, and
navitoclax interferes with this binding to trigger PDGF-primed
apoptosis.
PDGF-mediated Apoptotic Priming Is Bak- and Puma-
dependent—Although Bax and Bak are often viewed as being
functionally equivalent, the changes observed in Fig. 5A sug-
gested that Bak might play a more dominant role in PDGF-
induced priming of CAFs. To test this possibility, myofibro-
blasts with shRNA-mediated knockdown of Bak or Bax,
generated as previously described (3), were treated with
PDGF-B with and without navitoclax. As indicated in Fig. 6A,
Bax knockdown did not affect PDGF-B sensitization of myofi-
broblasts to cell death. In contrast, Bak knockdown markedly
diminished the ability of navitoclax to induce apoptosis in
PDGF-B treated shBak myofibroblasts (Fig. 6A), suggesting a
critical role for Bak.
Because Puma can directly activate Bak (40, 41), we postu-
lated that the PDGF-induced Puma up-regulation might be
responsible for Bak activation and binding to Bcl-2. To test this
prediction, myofibroblasts with shRNA-mediated knockdown
of Puma were treated with PDGF-B and navitoclax (Fig. 6, B,
and C). Knockdown of Puma prevented both the formation of
higher order Bak protein complexes (Fig. 6B) and the induction
of apoptosis by the PDGF-B/navitoclax combination (Fig. 6C),
placing Puma upstreamof Bak activation. Because PDGFmedi-
ates a decrease in Bcl-2 in some albeit not all myofibroblast cell
lines, we also employed siRNA-mediated knockdown of Bcl-2
to determine its role in PDGF-induced apoptotic sensitization.
Interestingly, myofibroblasts with knockdown of Bcl-2 dis-
FIGURE 4. PDGF increases cellular Puma levels. A, whole cell lysates were
prepared from quiescent hFB and HSC treated with vehicle (Veh) or PDGF-B
for 24h. Cell lysateswere subject to immunoblot analysis of theBcl-2 family of
proteins. Actin was used as a loading control. Except where indicated by
dashed lines, all lanes were adjacent on the membranes. B, expression of
Puma was assessed by quantitative real-time-PCR in HSC. Means  S.E. are
depicted for n 3.
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played a modest increase in apoptosis with PDGF-B alone,
and as expected a significant increase with the PDGF-B plus
navitoclax combination was observed (Fig. 6D). Collectively,
these observations suggest PDGF-B primes CAF for cell
death primarily via a Puma-dependent mechanism, although
down-regulation of Bcl-2 may also contribute to this altered
phenotype.
ABT-199 Functions Similar to Navitoclax in Sensitized
Myofibroblasts—ABT-199, a BH3 agonist being developed in
clinical trials, is structurally similar to navitoclax but differs
from it functionally in that it only binds Bcl-2 and not Bcl-xL
(42).We observed that ABT-199 also triggers apoptosis inmyo-
fibroblasts after PDGF-B treatment (Fig. 7A), similar to navito-
clax (Fig. 2A). This observation suggests a functional role for the
Bcl-2/Bak oligomers identified in Fig. 5 by suggesting a cytopro-
tective function for Bcl-2 in the PDGF-induced primed state.
Similar to navitoclax, the combination of PDGF-B and ABT-
199 also led to shifting of Bak from monomers to higher
order protein complexes (Fig. 7B). Finally, we demonstrated
that knockdown of Puma prevented both the formation of
FIGURE 5. Navitoclax interferes with PDGF-facilitated binding of Bak and Bcl-2 triggering Bak oligomerization. A, HSC cells were treated with vehicle
(Veh), PDGF-B, PDGF-D, navitoclax (Nav), and PDGF-B for 24 h followed by the addition of navitoclax for 24 h or PDGF-D for 24 h followed by the addition of
navitoclax for 24 h. Subsequently, whole cell lysates were subjected to FPLC and fractions underwent immunoblot analysis for Bax and Bak. B, HSC cells were
treatedwith vehicle, PDGF-B, navitoclax, or PDGF-B for 24 h followed by the addition of navitoclax for 24 h. Subsequently, whole cell lysates were subjected to
FPLC, and fractions underwent immunoblot analysis for Bcl-2. C, immunoprecipitation (IP) of Bcl-2 from cell lysates of HSC cells treated as described in Fig. 5B
and subsequent immunoblot analysis for Bak.
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higher order Bak protein complexes (Fig. 7C) and the induc-
tion of apoptosis by the PDGF-B/ABT-199 combination
(Fig. 7A). These data indicate that ABT-199 has a pharma-
cologic effect virtually identical to navitoclax in PDGF-
primed myofibroblasts.
ABT-199 Reduces Tumor Burden in a Murine Model of
Cholangiocarcinoma—We previously demonstrated that navi-
toclax reduces tumor burden in a syngeneic orthotopic rodent
model of CCA (3).We now sought to determine whether ABT-
199, a newer BH3mimetic with an improved safety profile, had
a similar therapeutic effect in amore robust model of CCA.We
recently generated a murine model of CCA combining ectopic
oncogene expression with constitutively active AKT and YAP
(Yes-associated protein) in the biliary tree combined with sys-
temic IL-33 administration (35). In thismodel-SMA-express-
ingmyofibroblasts first appear	6 weeks after biliary oncogene
transduction (data not shown). Hence, to examine a potential
therapeutic effect of ABT-199, mice were treated with this
agent for 2 weeks beginning on week 4 after oncogenic trans-
formation. ABT-199 significantly reduced tumor formation
FIGURE6.KnockdownofPumaorBak,butnotBax, confers resistance toPDGF-mediated sensitization tonavitoclax-inducedapoptosis.A, Bak andBax
were knocked down in HSC cells by shRNA technique, and cells were treated as described in Fig. 2A. Apoptosis was quantified using DAPI staining plus
fluorescencemicroscopy (upper panels) and bymeasuring caspase-3/7 activity (lower panels). Means S.E. are depicted for n 3. **, p 0.01; ***, p 0.001.
Veh, vehicle; Nav, navitoclax. B, Puma was knocked down in HSC cells by shRNA technique (Western blotting for Puma in empty vector (EV) and shPuma HSC
cells; left panel). shPuma HSC cells (clone 1 and 2) were treated as described in Fig. 5B and subjected to FPLC, and fractions subsequently underwent
immunoblot analysis for Bak (right panel).C, shPumacells (clones 1and2)were treatedasdescribed inFig. 2A. ApoptosiswasquantifiedusingDAPI stainingplus
fluorescence microscopy. Means S.E. are depicted for n 3. D, cells transfected with a specific siRNA for Bcl-2 (Western blotting for Bcl-2; left panel) were
treated as described in Fig. 5B. Cells transfected with scramble siRNA were used as a control. Apoptosis was quantified using DAPI staining plus fluorescence
microscopy. Means S.E. are depicted for n 3.
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comparedwith vehicle (Fig. 8A).Moreover, in themice that did
have tumor formation, ABT-199 reduced the tumor burden
(Fig. 8B). Serum alanine aminotransferase values were similar
in both groups, suggesting that ABT-199 did not induce signif-
icant injury in the adjacent liver (Fig. 8C). Histological exami-
nation of the adjacent liver also confirmed the absence of tissue
injury in the ABT-199-treated group (Fig. 8D). Histologically,
tumors occurring in mice that had received ABT-199 were less
desmoplastic with a reduction in myofibroblasts and had
decreased -SMA expression compared with tumors in the
vehicle group (Fig. 8D). Furthermore, these tumors had hollow,
acellular areas that likely represented areas of myofibroblast
depletion. Significant apoptosis within the tumors, as evi-
denced by an increase in TUNEL-positive cells, occurred with
ABT-199 (Fig. 8E). These apoptotic cells likely represented
both the initial myofibroblast death as well as secondary cancer
FIGURE7.ABT-199 inducesapoptosis in sensitizedmyofibroblasts in aBak- andPuma-dependentmanner.A, HSCand shPuma (clones 1 and 2) cellswere
treated as described in Fig. 2A. Apoptosis was quantified using DAPI staining plus fluorescencemicroscopy (top panel) and bymeasuring caspase-3/7 activity
(bottom panel). Veh, vehicle. Means S.E. are depicted for n 3. **, p 0.01. B, HSC cells were treated with vehicle, PDGF-B for 24 h, ABT-199 for 24 h, and
PDGF-B for 24 h followed by the addition of ABT-199 for 24 h. Subsequently, whole cell lysates were subjected to FPLC, and fractions underwent immunoblot
analysis for Bak. C, shPuma HSC cells were treated as described in B. Subsequently, whole cell lysates were subjected to FPLC, and fractions underwent
immunoblot analysis for Bak.
Cancer-associated Fibroblast Deletion for Cancer Therapy
AUGUST 15, 2014•VOLUME 289•NUMBER 33 JOURNAL OF BIOLOGICAL CHEMISTRY 22845
cell death. These data are consistent with a chemotherapeutic
role for ABT-199 via depletion of myofibroblasts from the
tumormicroenvironment of a highly desmoplasticmalignancy.
DISCUSSION
This study provides newmechanistic insights regarding CAF
apoptotic priming by PDGF. These data indicate that 1) PDGF
in the tumor microenvironment sensitizes CAF to apoptosis
through changes in cellular Puma levels, 2) PDGF-mediated
increases in Puma result in downstream formation of Bcl-2/Bak
protein complexes, and 3) these complexes can be disrupted by
BH3mimetics, inducing Bak-dependent cell death. These find-
ings are discussed in greater detail below.
Similar to activated T-cells in immune response and acti-
vated myofibroblasts in liver fibrosis, CAFs represent an acti-
vated state in desmoplastic cancers such as cholangiocarci-
noma (11–13). As such, CAFhave an enhanced susceptibility to
apoptosis (3). The biochemical basis for this effect has
FIGURE 8.ABT-199 reduces tumor burden in amurinemodel of cholangiocarcinoma. A, mice having undergone biliary oncogene transduction, systemic
IL-33 administration, and subsequent treatmentwith vehicle (Veh) or ABT-199 (50mg/kg/day) were euthanized and examined for the presence of tumors and
tumorburden. Themean is depicted forn8 (vehicle) andn9 (ABT-199). **,p0.01.B, tumors, if present,were carefully excised from the liver andweighed.
C, serum alanine aminotransferase values were measured by standard techniques in samples from mice treated with vehicle and ABT-199. D, representative
photomicrograph of hematoxylin and eosin-stained tumor sections and adjacent liver are shown (upper andmiddle panels, respectively). Characteristic tumor
areas are to the left of the dashed line. Immunohistochemistry was used to detect -SMA expression in tumors (lower panels). Original magnification. 20. E,
apoptotic cells were quantified by counting TUNEL-positive nuclei in 5 random microscopic fields (63) using a confocal microscope. Means  S.E. are
depicted. ***, p 0.001.
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remained obscure. Here we have observed that PDGF isomers
abundantly expressed by CCA cells sensitize myofibroblasts,
but not CCA cells, to apoptosis. Priming for BH3 mimetic-in-
duced cell death was not observed with other growth factors
expressed in CCA, thereby demonstrating specificity of this
effect of PDGF. These observations are also concordant with
prior publications suggesting that PDGF may directly induce
apoptosis in murine fibroblasts (43). Thus, despite being a
growth factor, PDGF may also sensitize cells to apoptosis, an
observation analogous to the concept of oncogene-induced cell
death (44).
A unified model of Bcl-2 protein interactions in the mito-
chondrial pathway of apoptosis was recently proposed (17). In
this unified model, two “modes” enable the antiapoptotic rep-
ertoire to block mitochondrial outer membrane permeabiliza-
tion, a critical step in the mitochondrial pathway of cell death.
The antiapoptotic Bcl-2 proteins sequester the direct-activator
BH3-only proteins in MODE 1 and Bax and Bak in MODE 2.
Under conditions of high stress or upon apoptotic stimulation,
direct activators such as Bid, Bim, and Puma directly bind Bak
or Bax, inducing changes conducive to their ability to permea-
bilize the outer mitochondrial membrane (17, 32, 45, 46). Anti-
apoptotic proteins such asMcl-1, Bcl-2, and Bcl-xL may in turn
sequester the activated effectors, precluding their oligomeriza-
tion. The present work indicates that PDGF is an apoptotic
stimulus leading to increases in levels of the direct activator
Puma in CAF. This in turn prompts changes in Bak, leading to
its subsequent binding to the antiapoptotic protein Bcl-2.
Although these PDGF-induced changes in Puma and Bak are
not sufficient to induce apoptosis by themselves, the BH3
mimetic navitoclax functions as a derepressor and releases Bak
fromBcl-2, allowing apoptosis. Thismodel, which suggests that
Bcl-2 is acting in MODE 2 to simultaneously prevent PDGF-
induced apoptosis but leave the cell in a primed state, is con-
sistent with the changes in Bak oligomerization observed under
various conditions (Figs. 5 and 6) as well as the effects of PDG-
FRB, Bak, and Puma knockdowns (Figs. 3 and 6).
Bak and Bax often are redundant in the mitochondrial path-
way of cell death, especially in fibroblasts (47). Hence, our
observation that Puma priming of CAF for cell death was Bak-
dependent was unexpected, especially because Puma can acti-
vate either Bak or Bax (40, 41). Additionally, in our prior studies
using CAF, Bax was found to participate in the priming phe-
nomenon (3). Close examination of Fig. 5A indicates that PDGF
causes a small amount of Bax to form oligomers as well. How-
ever, the extent of Bax oligomerization is lower than the extent
of Bak oligomerization. These observations suggest PDGF
induces a specific cellular context in regard to apoptotic prim-
ing and that other priming phenomena yet to be defined may
engage Bax. The relative roles of these two apoptotic mediators
in CAF apoptotic priming in vivo will require further mecha-
nistic studies.
The current data suggest that PDGF-B signaling pathways
increase cellular levels of Puma, which in turn, is essential for
Bak activation and apoptosis priming. The increase in Puma
appears to be independent of transcription, as steady state
mRNA Puma expression in myofibroblasts was unaltered by
PDGF-B treatment. Although decreases inmicroRNA221, 222,
296, and 483 could potentially explain enhanced protein tran-
scription in the absence of transcriptional activation (49–51),
we did not observe changes in these microRNA after exposure
to PDGF-B (data not shown). Perhaps loss of other yet to be
examined microRNA are responsible for the increase in Puma.
We are currently exploring this concept. Phosphorylation of
Puma by MAPK and IB kinase (IKK) may decrease protein
stability (48), suggesting that phosphatasesmay enhance its sta-
bility. The precise phosphatase responsible for this effect is
unclear and remains to be determined in future investigations.
Our data suggesting a protective role for Bcl-2 in PDGF-
mediated CAF apoptotic priming prompted investigation of a
newer BH3 mimetic, ABT-199. Navitoclax, the first orally bio-
available Bcl-2 family inhibitor, inhibits Bcl-2 and Bcl-xL. Inhi-
bition of the latter results in dose-limiting thrombocytopenia
(18). ABT-199, a potent Bcl-2 inhibitor, was subsequently
designed in an effort to spare platelets and allow higher circu-
lating levels of the drug in patients with hematopoietic malig-
nancies. It showed significant promise in preclinical studies by
induction of apoptosis in hematological cancer cell lines and
tumor regression in vivo (42) and is currently being evaluated in
clinical trials.We have now demonstrated a proapoptotic effect
of ABT-199 on myofibroblasts primed for apoptosis. ABT-199
was found to be mechanistically similar to navitoclax in our
model; hence, its proapoptotic effect was also Bak- and Puma-
dependent. Additionally, ABT-199 reduced tumor formation
and tumor burden in a murine model of CCA via depletion of
myofibroblasts from the tumor stroma. Accordingly, targeting
the tumor stroma in desmoplastic malignancies represents a
novel and promising role for this new BH3 mimetic. Further
preclinical studies are warranted to determine the efficacy of
ABT-199 in desmoplastic malignancies.
In summary, the current study advances our understanding
of both CAF biology and cellular priming for apoptosis. The
present observations implicate PDGF-B and -D isoforms in
inducing CAF priming for cell death in the tumor microenvi-
ronment. These PDGF isoforms induce this altered cellular
state by increasing levels of the proapoptotic protein Puma.
These observations raise the possibility that PDGF and/or
Puma expression in desmoplastic tumors might serve as bio-
markers for this priming phenomenon. In addition, our data
provide new insight into the primed state. Previously, BH3
mimetics such as navitoclax were thought to displace activator
BH3 proteins from antiapoptotic Bcl-2 proteins, thereby liber-
ating them to activate Bak or Bax. The current observations
based on FPLC and immunoprecipitation of protein complexes
suggest that BH3-mimetics might kill primed cells by disrupt-
ing preformed complexes between antiapoptotic Bcl-2 proteins
and activated Bak or Bax, permitting the latter to execute the
cell death program. Furthermore, these data suggest that BH3
mimetics may be therapeutic in desmoplastic cancers by delet-
ing CAF, a concept warranting further explanation in preclini-
cal and perhaps clinical studies.
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